Summary：HMNC Brain Health Secures $50M Financing, Forges Game-Changing Medical PartnershipMUNICH, Germany, J

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

HMNC Brain Health Secures $50M Financing, Forges Game-Changing Medical Partnership

MUNICH, Germany, June 15, 2026 – In a significant milestone for the neuroscience industry, HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the successful $50 million first closing of its Series B financing. This substantial investment will fuel the advancement of the Company's innovative Ketabon (KET01) treatment, poised to revolutionize the management of neurological disorders.

The key developments driving HMNC's progress include the strategic allocation of the Series B funds towards accelerating the clinical development of Ketabon (KET01), a novel therapeutic approach demonstrating immense potential in addressing unmet medical needs. Furthermore, HMNC has entered into a groundbreaking partnership with a leading medical research institution, facilitating the exchange of cutting-edge research and expertise. This collaboration is expected to fast-track the development of Ketabon and enhance its clinical efficacy.

The neuroscience industry is witnessing a paradigm shift with the emergence of innovative treatments like Ketabon. As the global prevalence of neurological disorders continues to rise, the demand for effective therapeutic solutions is escalating. HMNC's pioneering work in this domain is set to redefine the treatment landscape, offering new hope to patients and healthcare providers alike. Industry analysts predict that the successful development and commercialization of Ketabon could significantly impact the market dynamics, driving growth and innovation.

With the $50 million financing in place, HMNC is poised to achieve several key milestones in the near future. The Company is expected to initiate pivotal clinical trials for Ketabon, leveraging the expertise and resources garnered through its strategic partnership. As the clinical development program progresses, HMNC is likely to attract further investment, underscoring the confidence of investors in the Company's vision and capabilities.

In conclusion, HMNC Brain Health's achievement marks a significant breakthrough in the neuroscience industry. The successful $50 million Series B financing and the strategic medical partnership underscore the Company's commitment to advancing innovative treatments. As HMNC continues to push the boundaries of neurological care, its progress is expected to have far-reaching implications for patients, healthcare providers, and the industry at large.